Floatz logo

Hycamtin

Recurrent Wilms Tumor and Other Childhood Kidney Tumors

Emory UniversityPhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Recurrent Wilms Tumor and Other Childhood Kidney Tumors cohort.

Asset / SponsorPhaseRating
Inno-206
Children's National Research Institute
Phase 2BB
(+)-VINCRISTINE
Centre Oscar Lambret
Phase 2BB
Itraconazole
Samsung Medical Center
Phase 4BB
Irinotecan
Centre Oscar Lambret
Phase 2BB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →